CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Chlorhexidine digluconate, povidone iodinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04941131
NCT04941131Phase 4Completed

The Role of Chlorhexidine in Minimizing the Viral Load Among COVID-19 Patients: A Randomized Controlled Clinical Trial

King Abdulaziz University·interventional·Posted Jun 28, 2021·Updated Jun 12, 2025

In Brief

A Phase 4 clinical trial evaluating Chlorhexidine digluconate, povidone iodine for COVID-19. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Existing evidence confirmed that saliva and oral cavity to be a reservoir for SARS-CoV-2. In dental clinic aerosol-producing-procedures pose a significant risk for transmission of the infection . It is very important to minimize the risk of transmission in dental office reducing the load of SARS-CoV-2 in saliva if possible, in suspect or conformed cases. Preprocedural mouth rises have been used widely to minimize the number of oral microorganisms. Multiple studies confirmed the efficacy of those mouth rinses in reducing the possibility of transmission of SARS-CoV-2 infection .

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesSaudi Arabia
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedJun 28, 2021
Enrollment StartMay 18, 2023
Primary CompletionJul 25, 2023
Study CompletionAug 20, 2023
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.0 years ago

Interventions

Chlorhexidine digluconate, povidone iodinedrug

This is a mouth wash that can be used over the counter.